Overview

Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission

Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce the risk of colorectal cancer. Patients with ulcerative colitis are at increased risk for colorectal cancer. Chemoprevention is the use of drugs, such as berberine chloride, to keep a disease/condition from forming or coming back. The use of berberine chloride may keep colorectal cancer from forming in patients with ulcerative colitis.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)